It is unclear whether the sFlt-1/PlGF ratio is of added value to standard-of-care analyses performed in multiple pregnancies.
•The sFlt-1/PlGF cut-off 38 in addition to urine PCr did not enhance pre-eclampsia prediction in multiple pregnancy.
•The sFlt-1/PlGF ratio's impact on morbidity, cost-effectiveness in multiple pregnancies remains debatable.
AbstractObjectiveTo assess the predictive accuracy of the sFlt-1/PlGF ratio cut-off 38 in addition to the standard-of-care spot urine protein/creatinine ratio (PCr) for multiple pregnancies in women with suspected pre-eclampsia.
Study designPost-hoc analysis of a prospective cohort study.
Main outcome measuresPrimary outcome was the occurrence of pre-eclampsia in one and four weeks after presentation with suspected pre-eclampsia. Test characteristics with 95% confidence intervals (CI) were calculated on pre-eclampsia development in one and four weeks.
ResultsTwenty-three multiple pregnancies with suspected pre-eclampsia between 20 and 37 weeks gestation were included for analysis. Women who eventually developed pre-eclampsia had a significantly higher PCr (34.0 vs. 16.5, p = 0.015), sFlt-1 (17033 vs. 5270 pg/ml, p = 0.047) and sFlt-1/PlGF ratio (99 vs. 25, p = 0.033) at baseline. Furthermore, PCr ≥ 30 and sFlt-1/PlGF ratio > 38 was respectively seen in 1/16 (6.3 %) and 3/16 (18.8 %) of the women who did not develop pre-eclampsia. For predicting pre-eclampsia within one week the sFlt-1/PlGF ratio sensitivity was 75.0 % [95 % CI 19.4–99.4] and the negative predictive value 93.8 % [73.0–98.8], while no pre-eclampsia developed when PCr was < 30. Consequently, the combination of these tests did not lead to an improvement in test characteristics, with non-significant differences in positive predictive value (50.0 % [29.5–70.5] versus 80.0 % [37.3–96.4]) compared to PCr alone for pre-eclampsia development in one week.
ConclusionsIn addition to standard-of-care spot urine PCr measurements, this study has not been able to demonstrate that the sFlt-1/PlGF ratio cut-off 38 is of added value in the prediction of pre-eclampsia in multiple pregnancy.
Trial registration: Netherlands Trial Register (NL8308).
AbbreviationsPREPAREPREdiction of Pre-eclampsia and AdveRse Events
LUMCLeiden University Medical Centre
sFlt-1Soluble FMS-like tyrosine kinase-1
PIGFPlacental growth factor
PCrspot urine protein/creatinine ratio
ALTalanine aminotransferase
ASTaspartate aminotransferase
FGRfetal growth restriction
NICUneonatal intensive care-unit
ISSHPInternational Society for the Study of Hypertension in Pregnancy
SPSSStatistical Package for the Social Sciences
KeywordsPre-eclampsia
Multiple pregnancy
Biomarkers
sFlt-1/PlGF ratio
© 2024 The Author(s). Published by Elsevier B.V. on behalf of International Society for the Study of Hypertension in Pregnancy.
Comments (0)